In vitro, ADU-S100 (a STING agonist)-treated cervical cancer cells exhibited reduced cell viability in a dose-dependent manner, accompanied by the upregulation of STING/IFN-β/IL-6 expression (11). The gene discussed is STING1; the disease is cervical carcinoma.